Loss of control of HIV viremia associated with the fat malabsorption drug orlistat.

@article{Kent2012LossOC,
  title={Loss of control of HIV viremia associated with the fat malabsorption drug orlistat.},
  author={Stephen J Kent},
  journal={AIDS research and human retroviruses},
  year={2012},
  volume={28 9},
  pages={
          961-2
        }
}
Editor: A 34-year-old previously healthy HIV + man was started on Atripla (daily combined tenofovir 300 mg/ emtricitibine 200 mg/efavirenz 600 mg) for a declining CD4 T cell count in February 2009. His HIV plasma RNA levels declined to < 50 copies/ml within 5–8 months and remained at < 50 copies/ml for the next year and his CD4 T cell rose (Fig. 1). He gained excess weight after starting Atripla and purchased over-the-counter orlistat (Xenical) from his local pharmacy in September 2010 to lose… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Orlistat: weight lost at cost of HIV rebound.

  • The Journal of antimicrobial chemotherapy
  • 2016

The anti-obesity drug orlistat reveals anti-viral activity

  • Medical Microbiology and Immunology
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND